{"id":516,"date":"2011-12-20T14:45:24","date_gmt":"2011-12-20T19:45:24","guid":{"rendered":"http:\/\/www.ptca.org\/voice\/?p=516"},"modified":"2013-07-11T13:40:36","modified_gmt":"2013-07-11T20:40:36","slug":"boston-scientifics-new-drug-eluting-stent-in-the-news-again","status":"publish","type":"post","link":"http:\/\/www.ptca.org\/voice\/2011\/12\/20\/boston-scientifics-new-drug-eluting-stent-in-the-news-again-516","title":{"rendered":"Boston Scientific’s New Drug-Eluting Stent in the News Again"},"content":{"rendered":"
\"Boston

Which stent platform do you think compresses more easily: Boston Scientific’s Element (top) or Medtronic’s Integrity (bottom)?<\/p><\/div>\n

I first heard concerns about stent deformation, primarily seen in the PROMUS Element stent made by Boston Scientific (NYSE: BSX), during a presentation at a small interventional meeting last summer. The issue was then reported in two journal articles, just prior to the TCT meeting in November, where it became a topic of much attention — although most interventional cardiologists felt that it was nothing like the problem of late stent thrombosis, first seen as a “rare” event in the first generation of drug-eluting stents five years ago.<\/span><\/p>\n

I reported extensively on longitudinal stent deformation a few weeks ago when Dr. John Ormiston’s article in JACC Interventions<\/em> was published. Angioplasty.Org’s coverage can be read in the following articles:<\/span><\/p>\n